To include your compound in the COVID-19 Resource Center, submit it here.

Analyst picks & changes

Texas Biotechnology Corp.

(TXB)

D. Blech & Co. analyst Michael King initiated coverage with a "buy" and a one-year price target of

Read the full 228 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE